The non-profit research institution FutureHouse published a significant paper in the prestigious academic journal Nature, officially unveiling the world's first multi-agent AI system capable of achieving "full closed-loop automation" in scientific discovery—Robin. In less than two hours, the system completed an amount of work that typically takes human scientists nearly four months, or about 900 hours.
Like an tireless dream team of researchers
Robin's breakthrough lies in its clever integration of three clearly defined AI agents, connecting the entire process from hypothesis generation to hypothesis validation. The "Crow" agent is responsible for quickly scanning vast amounts of literature and determining experimental strategies, the "Falcon" agent conducts in-depth evaluations, while the "Finch" agent specializes in data analysis, independently writing code, and creating rigorous statistical charts.
In a practical test targeting the blinding eye disease "dry age-related macular degeneration (dAMD)," Robin consumed hundreds of documents in just half an hour. It not only accurately identified the core pathogenic mechanism—the impaired phagocytic function of retinal pigment epithelial cells in the eye, but also precisely screened multiple potential new drugs from a large drug library, significantly shortening the early phase of drug development.
Autonomously cracking pharmacology and opening new directions
After human scientists conducted in vitro cell experiments based on the list of candidates proposed by Robin, they confirmed that the glaucoma clinical drug "Ripasudil" has remarkable potential for repurposing. Even more astonishingly, when facing experimental data, Robin autonomously proposed and designed an RNA sequencing (RNA-seq) plan, successfully deciphering the underlying pharmacological mechanisms of the drug.
During the data analysis process, Robin even uncovered a long-overlooked clue of significant upregulation of the "ABCA1" gene, opening an unexpected new direction for the development of novel targeted therapies for this eye disease. This disruptive efficiency and insight mark the beginning of a completely new era in AI-driven scientific discovery.
